{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T09:31:20Z","timestamp":1683538280146},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T00:00:00Z","timestamp":1596499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chirurg"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>B\u00f6sartige Schilddr\u00fcsentumoren sind die h\u00e4ufigsten b\u00f6sartigen endokrinen Tumoren, die ungef\u00e4hr 1\u202f% aller malignen Tumoren umfassen. In den letzten Jahren ist die Inzidenz des differenzierten Schilddr\u00fcsenkarzinoms (DTC) deutlich angestiegen, insbesondere der kleinen papill\u00e4ren Karzinome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Fragestellung<\/jats:title>\n                <jats:p>Dargestellt werden Indikationen und Ergebnisse der Radiojodtherapie (RJT) beim DTC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>Es erfolgt die Durchsicht der aktuellen Literatur und Leitlinien zur RJT des DTC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Die RJT stellt die wichtigste adjuvante Behandlungsoption des DTC dar und wird generell gut vertragen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Schlussfolgerungen<\/jats:title>\n                <jats:p>Verglichen mit anderen Tumoren hat das DTC durch die Kombination von Operation und RJT eine sehr gute Prognose mit einer durchschnittlichen \u00dcberlebensrate von \u00fcber 90\u202f%.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00104-020-01248-x","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T12:02:36Z","timestamp":1596542556000},"page":"1013-1016","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Indikationen und Ergebnisse der Radiojodtherapie beim differenzierten Schilddr\u00fcsenkarzinom"],"prefix":"10.1007","volume":"91","author":[{"given":"B.","family":"Riemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,4]]},"reference":[{"key":"1248_CR1","doi-asserted-by":"publisher","first-page":"190","DOI":"10.2967\/jnumed.114.150284","volume":"56","author":"TM Maier","year":"2015","unstructured":"Maier\u00a0TM, Schober\u00a0O, Ger\u00df\u00a0J, G\u00f6rlich\u00a0D, Wenning\u00a0C, Sch\u00e4fers\u00a0M, Riemann\u00a0B, Vrachimis\u00a0A (2015) Differentiated thyroid cancer patients more than 60 years old paradoxically show an increased life expectancy. J\u00a0Nucl Med 56:190\u2013195","journal-title":"J Nucl Med"},{"key":"1248_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1055\/s-0037-1616478","volume":"55","author":"M Dietlein","year":"2016","unstructured":"Dietlein\u00a0M, Eschner\u00a0W, Gr\u00fcnwald\u00a0F, Lassmann\u00a0M, Verburg\u00a0FA, Luster\u00a0M (2016) Procedure guidelines for radioiodine therapy of differentiated thyroid cancer. Nuklearmedizin 55:77\u201389","journal-title":"Nuklearmedizin"},{"key":"1248_CR3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1055\/a-0891-1839","volume":"58","author":"FA Verburg","year":"2019","unstructured":"Verburg\u00a0FA, Schmidt\u00a0M, Kreissl\u00a0MC, Gr\u00fcnwald\u00a0F, Lassmann\u00a0M, H\u00e4nscheid\u00a0H, Hohberg\u00a0M, Luster\u00a0M, Dietlein\u00a0M (2019) Procedural guideline for Iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma (version 5). Nuklearmedizin 58:228\u2013241","journal-title":"Nuklearmedizin"},{"key":"1248_CR4","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2967\/jnumed.116.179606","volume":"58","author":"D Deandreis","year":"2017","unstructured":"Deandreis\u00a0D, Rubino\u00a0C, Tala\u00a0H, Leboulleux\u00a0S, Terroir\u00a0M, Baudin\u00a0E, Larson\u00a0S, Fagin\u00a0JA, Schlumberger\u00a0M, Tuttle\u00a0RM (2017) Comparison of empiric versus whole-body\/-blood clearance dosimetry-based approach to radioactive iodine treatment in patients with metastases from differentiated thyroid cancer. J\u00a0Nucl Med 58:717\u2013722","journal-title":"J Nucl Med"},{"key":"1248_CR5","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1089\/thy.2014.0460","volume":"25","author":"GL Francis","year":"2015","unstructured":"Francis\u00a0GL, Waguespack\u00a0SG, Bauer\u00a0AJ, Angelos\u00a0P, Benvenga\u00a0S, Cerutti\u00a0JM, Dinauer\u00a0CA, Hamilton\u00a0J, Hay\u00a0ID, Luster\u00a0M, Parisi\u00a0MT, Rachmiel\u00a0M, Thompson\u00a0GB, Yamashita\u00a0S, American Thyroid Association Guidelines Task Force (2015) Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid 25:716\u2013759","journal-title":"Thyroid"},{"key":"1248_CR6","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1210\/jc.2013-3156","volume":"99","author":"L Giovanella","year":"2014","unstructured":"Giovanella\u00a0L, Treglia\u00a0G, Sadeghi\u00a0R, Trimboli\u00a0P, Ceriani\u00a0L, Verburg\u00a0FA (2014) Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: a meta-analysis. J\u00a0Clin Endocrinol Metab 99:440\u2013447","journal-title":"J Clin Endocrinol Metab"},{"key":"1248_CR7","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s00259-015-3195-2","volume":"43","author":"A Vrachimis","year":"2016","unstructured":"Vrachimis\u00a0A, Burg\u00a0MC, Wenning\u00a0C, Allkemper\u00a0T, Weckesser\u00a0M, Sch\u00e4fers\u00a0M, Stegger\u00a0L (2016) 18F]FDG PET\/CT outperforms [18F]FDG PET\/MRI in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 43:212\u2013220","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1248_CR8","first-page":"267","volume":"63","author":"L Giovanella","year":"2019","unstructured":"Giovanella\u00a0L, van Nostrand\u00a0D (2019) Advanced differentiated thyroid cancer: when to stop radioiodine? Q\u00a0J Nucl Med Mol Imaging 63:267\u2013270","journal-title":"Q J Nucl Med Mol Imaging"}],"container-title":["Der Chirurg"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-020-01248-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00104-020-01248-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-020-01248-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T23:07:21Z","timestamp":1628032041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00104-020-01248-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,4]]},"references-count":8,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1248"],"URL":"https:\/\/doi.org\/10.1007\/s00104-020-01248-x","relation":{},"ISSN":["0009-4722","1433-0385"],"issn-type":[{"value":"0009-4722","type":"print"},{"value":"1433-0385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,4]]},"assertion":[{"value":"4 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"B.\u00a0Riemann gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}